{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Siebert N"],"funding":["Cancer Research UK","Deutsche Kinderkrebsstiftung"],"pagination":["387"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6210332"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(10)"],"pubmed_abstract":["GD₂-directed immunotherapies improve survival of high-risk neuroblastoma (NB) patients (pts). Treatment with chimeric anti-GD₂ antibodies (Ab), such as ch14.18, can induce development of human anti-chimeric Ab (HACA). Here, we report HACA effects on ch14.18/CHO pharmacokinetics, pharmacodynamics and pain intensity in pts treated by long-term infusion (LTI) of ch14.18/CHO combined with IL-2. 124 pts received up to 5 cycles of ch14.18/CHO 10 days (d) infusion (10 mg/m²/d; d8⁻18) combined with s.c. IL-2 (6 × 10⁶ IU/m²/d; d1⁻5, d8⁻12). HACA, treatment toxicity, ch14.18/CHO levels, Ab-dependent cellular- (ADCC) and complement-dependent cytotoxicity (CDC) were assessed using respective validated assays. HACA-negative pts showed a steadily decreased pain in cycle 1 (74% pts without morphine by d5"],"journal":["Cancers"],"pubmed_title":["Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial."],"pmcid":["PMC6210332"],"funding_grant_id":["14042","DKS 2014.05 A/B"],"pubmed_authors":["Ehlert K","Ash S","Siebert N","Castel V","Manzitti C","Klingebiel T","Beck J","Garaventa A","Troschke-Meurer S","Gray J","Lode HN","Marx M","Ladenstein R","Zumpe M","Valteau-Couanet D","Loibner H"],"additional_accession":[]},"is_claimable":false,"name":"Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.","description":"GD₂-directed immunotherapies improve survival of high-risk neuroblastoma (NB) patients (pts). Treatment with chimeric anti-GD₂ antibodies (Ab), such as ch14.18, can induce development of human anti-chimeric Ab (HACA). Here, we report HACA effects on ch14.18/CHO pharmacokinetics, pharmacodynamics and pain intensity in pts treated by long-term infusion (LTI) of ch14.18/CHO combined with IL-2. 124 pts received up to 5 cycles of ch14.18/CHO 10 days (d) infusion (10 mg/m²/d; d8⁻18) combined with s.c. IL-2 (6 × 10⁶ IU/m²/d; d1⁻5, d8⁻12). HACA, treatment toxicity, ch14.18/CHO levels, Ab-dependent cellular- (ADCC) and complement-dependent cytotoxicity (CDC) were assessed using respective validated assays. HACA-negative pts showed a steadily decreased pain in cycle 1 (74% pts without morphine by d5","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Oct","modification":"2025-04-04T22:21:43.673Z","creation":"2019-03-27T00:05:45Z"},"accession":"S-EPMC6210332","cross_references":{"pubmed":["30336605"],"doi":["10.3390/cancers10100387"]}}